<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043077</url>
  </required_header>
  <id_info>
    <org_study_id>23265/14-07-2021</org_study_id>
    <nct_id>NCT05043077</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening</brief_title>
  <acronym>MyMiROPS</acronym>
  <official_title>Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening: a Non-inferiority Crossover Randomized Controlled Trial (MyMiROPS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to test the hypothesis that microdrop instillation of combined phenylephrine&#xD;
      1.67% and tropicamide 0.33% eyedrops causes at least equal mydriasis compared with standard&#xD;
      drop instillation of the same mydriatic regimen, which constitutes routine care for pupil&#xD;
      dilation during retinopathy of prematurity (ROP) screening in our neonatal intensive care&#xD;
      unit. Comparison, also, will be made to the subsequent adverse events and the drug&#xD;
      concentration in peripheral blood samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-inferiority, crossover, randomized controlled trial will be conducted for this purpose.&#xD;
      Participants will be randomly assigned to receive either a) microdrops on their first and&#xD;
      standard drops on their second screening examination a week later (M/S group), or b) standard&#xD;
      drops first and microdrops a week later (S/M group). Microdrops (6.5 μL) will be instilled&#xD;
      using a calibrated micropipette, while standard drops (28-34 μL) will be instilled directly&#xD;
      through the commercially available plastic multi-dose mydriatic dropper bottle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mydriatic efficacy: millimeters of horizontal pupil diameter.</measure>
    <time_frame>45 minutes after the first drop instillation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mydriasis sustainability: millimeters of horizontal pupil diameter.</measure>
    <time_frame>90 minutes after the first drop instillation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mydriasis sustainability: millimeters of horizontal pupil diameter.</measure>
    <time_frame>120 minutes after the first drop instillation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of phenylephrine: area under the whole blood concentration versus time curve (AUC).</measure>
    <time_frame>Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.</time_frame>
    <description>Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of phenylephrine: maximum (peak) whole blood concentration (Cmax).</measure>
    <time_frame>Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.</time_frame>
    <description>Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of phenylephrine: time to reach maximum (peak) whole blood concentration (Tmax).</measure>
    <time_frame>Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.</time_frame>
    <description>Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of phenylephrine: elimination half-life (T1/2).</measure>
    <time_frame>Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.</time_frame>
    <description>Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate values (beats per minute).</measure>
    <time_frame>45, 90 and 120 minutes after the first drop instillation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation (SpO2) values (%).</measure>
    <time_frame>45, 90 and 120 minutes after the first drop instillation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic, diastolic, and mean blood pressure values (mmHg).</measure>
    <time_frame>45, 90 and 120 minutes after the first drop instillation. Hourly blood pressure measurements for the first 24 hours after mydriasis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with systemic adverse events.</measure>
    <time_frame>During the 48 hours after mydriasis.</time_frame>
    <description>Apnea, increased gastric residuals, inhibited duodenal motor activity, delayed gastric emptying, feeding intolerance, abdominal distension, vomiting, paralytic ileus, acute gastric dilatation, necrotizing enterocolitis (NEC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with local adverse events.</measure>
    <time_frame>45 minutes after the first drop instillation.</time_frame>
    <description>Periorbital pallor, eyelid swelling, flushing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of judging the presence or absence of treatment-requiring ROP.</measure>
    <time_frame>At the end of the eye examination (fundoscopy).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mydriasis with microdrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mydriasis with standard drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%</intervention_name>
    <description>1 drop (6.5 μL) for 3 doses with 5-minute intervals</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%</intervention_name>
    <description>1 drop (28-34 μL) for 3 doses with 5-minute intervals</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Preterm infants undergoing screening for ROP, i.e.&#xD;
&#xD;
          -  infants with GA &lt; 32 weeks and/or BW &lt; 1501 grams&#xD;
&#xD;
          -  infants of greater GA and BW with comorbidities, e.g. sepsis, prolonged need for&#xD;
             oxygen supplementation etc., as recommended by the attending neonatologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable clinical condition&#xD;
&#xD;
          -  Severe cardiovascular disease&#xD;
&#xD;
          -  Congenital anomalies&#xD;
&#xD;
          -  Clinical syndromes&#xD;
&#xD;
          -  Inotropes' intake during the week prior to enrollment&#xD;
&#xD;
          -  Traumatic apoptosis of the corneal epithelium&#xD;
&#xD;
          -  Corneal ulcer&#xD;
&#xD;
          -  Anatomical variations of the anterior segment&#xD;
&#xD;
          -  Infants that are outpatients at the commencement of ROP screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asimina Mataftsi, MD, MRCOphth, PhD</last_name>
      <phone>+30 6985 071555</phone>
      <email>amatafts@auth.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Lynch MG, Brown RH, Goode SM, Schoenwald RD, Chien DS. Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption. Arch Ophthalmol. 1987 Oct;105(10):1364-5.</citation>
    <PMID>3662909</PMID>
  </reference>
  <reference>
    <citation>Elibol O, Alçelik T, Yüksel N, Caglar Y. The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants. Acta Ophthalmol Scand. 1997 Apr;75(2):178-80.</citation>
    <PMID>9197568</PMID>
  </reference>
  <reference>
    <citation>Seliniotaki AK, Prousali E, Lithoxopoulou M, Kokkali S, Ziakas N, Soubasi V, Mataftsi A. Alternative mydriasis techniques for retinopathy of prematurity screening. Int Ophthalmol. 2020 Dec;40(12):3613-3619. doi: 10.1007/s10792-020-01542-x. Epub 2020 Aug 9. Review.</citation>
    <PMID>32772218</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Asimina Mataftsi</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology, Paediatric Ophthalmology and Strabismus</investigator_title>
  </responsible_party>
  <keyword>microdrops</keyword>
  <keyword>mydriasis</keyword>
  <keyword>dilating drops</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>tropicamide</keyword>
  <keyword>retinopathy of prematurity</keyword>
  <keyword>ROP</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified Individual Participant Data (IPD) that underline published results, along with related data dictionaries, will be available from 3 months to 36 months following article publication, only to researchers who will provide a methodologically sound proposal, for types of analyses to achieve aims in the approved proposal or for individual participant data meta-analysis, and only after acceptance of the proposed protocol by our Institution's IRB. Proposals should be directed to the corresponding author (AM, amatafts@auth.gr) and data requestors will need to sign a data access agreement. The study protocol and statistical analysis plan will also be available, if needed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

